BASEL, Switzerland ( TheStreet) -- Novartis ( NVS), the Swiss drugmaker, said first-quarter earnings fell 4% because of additional financing costs related to the acquisition of the rest of eye care company Alcon ( ACL).

Novartis earned $2.82 billion in the first quarter, down from $2.95 billion a year earlier.

Analysts were expecting profits of $2.6 billion in the first quarter.

Novartis said sales rose 16% to $14.03 billion, or 14% in constant currencies. The company said sales benefited by 2% as the dollar weakened against most currencies.

Pharmaceuticals sales rose 7% in the quarter to $7.8 billion.

Novartis completed the acquisition of Alcon on April 8. Alcon contributed $1.9 billion toward first-quarter sales.

Novartis said it expects double-digit sales growth for the full year.

-- Written by Joseph Woelfel

>To contact the writer of this article, click here: Joseph Woelfel

>To submit a news tip, send an email to: tips@thestreet.com.
Copyright 2011 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. AP contributed to this report.

If you liked this article you might like

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug

Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug

Axovant Shares Crater as CEO and President Both Resign

Axovant Shares Crater as CEO and President Both Resign

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget